Bioxytran (BIXT) Current Deferred Revenue (2017)
Bioxytran (BIXT) posted Current Deferred Revenue of $4800.0 for Q4 2017.
Bioxytran (BIXT) Current Deferred Revenue (2017) Analysis & Trends
Bioxytran has reported Current Deferred Revenue for 1 years, with the latest figure at $4800.0 in Q4 2017.
- Quarterly Current Deferred Revenue changed N/A year-over-year to $4800.0 in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $4800.0 (changed N/A YoY) and the FY2017 annual result came in at $4800.0, changed N/A from the prior year.
- Current Deferred Revenue steadied at $4800.0 in Q4 2017 per BIXT's latest filing.
- Over five years, Current Deferred Revenue peaked at $4800.0 in Q4 2017 and troughed at $4800.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Bioxytran | 2.47 Mn | 2.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 4,800.00 |